Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
70Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-3.35M | $-0.05 |
| 2024 | $0.00 | $-156.81M | $-2.70 |
| 2023 | $0.00 | $-117.81M | $-1.88 |
| 2022 | $0.00 | $47.42M | $0.46 |
| 2021 | $0.00 | $-111.41M | $-1.79 |
Social Signal Score
Earnings
Thu, Nov 12(in 3 months)
Consensus estimate $-0.22 per share
Typical surprise +40.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$0.15 vs $-0.27beat
- Wed, May 13$-0.24 vs $-0.40beat
- Tue, Mar 31$3.14 vs $-0.55beat
- Thu, Nov 13$-0.19 vs $-0.58beat
- Thu, Aug 14$-0.53 vs $-0.55beat
- Thu, May 15$-0.65 vs $-0.57miss
Estimates and results for OMER via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
OMERhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (5)
- Newsdefenseworld.net·12h ago·Positive
Omeros Corporation (NASDAQ:OMER) Receives Consensus Recommendation of “Moderate Buy” from Brokerages Shares of Omeros Corporation (NASDAQ: OMER - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six analysts that are covering the company, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and one has issued a strong buy recommendation on the
View source ↗ - Newsseekingalpha.com·2d ago·Positive
Omeros Corporation (OMER) Q2 2026 Earnings Call Transcript Omeros Corporation (OMER) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·2d ago·Neutral
Omeros Q2 Earnings Call Highlights Omeros NASDAQ: OMER reported second-quarter net sales of $28.5 million for YARTEMLEA, its newly launched treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA, as the company generated positive operating cash flow and reduced its convertible debt after the quarter ended.
View source ↗ - Newszacks.com·2d ago·Neutral
Omeros (OMER) Q2 Earnings and Revenues Beat Estimates Omeros (OMER) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.27 per share. This compares to a loss of $0.53 per share a year ago.
View source ↗ - Newsbusinesswire.com·5d ago·Neutral
Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026 SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the second quarter of 2026 on Wednesday, August 12, 2026 after market close. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss recent developments and highlights as well as the Company's financial results. Confer
View source ↗